이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Impact of Pharmacotherapy Optimization in Polymedicated Lebanese Older Adults in Primary Health Care Centers (PHARMACT-PHC)

Pharmacotherapy Review and Optimization: Impact on Clinical Outcomes, Social Determinants of Health, and Quality of Life Among Polymedicated Lebanese Older Patients in the Primary Healthcare Setting Amidst Crises

Why are the researchers doing this study? Many older adults take five or more medicines every day. Some of these medicines may no longer help them. Some may even cause harm, such as falls, confusion or tiredness. At the same time, a medicine the person needs may be missing.

The researchers want to find out whether a careful review of a person's medicines helps older adults stay well. They will look at intrinsic capacity. This means the physical and mental abilities a person can draw on: memory and thinking, walking and moving, eating well, mood, eyesight and hearing. They will also look at quality of life, daily life, health and social conditions.

This kind of study has not been done before in primary health care centers in Lebanon.

Who can take part?

You may be able to join if you:

  • are 65 years old or older
  • have been a patient at one of the health centers for at least one year
  • take five or more medicines for long-term health problems
  • can carry out your daily activities on your own What will happen in the study? About 452 people will join at the primary health care centers of the Order of Malta Lebanon.

A computer will place each person in one of two groups, by chance, like the toss of a coin. About half (226 people) will be in each group:

  • In the first group, a pharmacist will go through all of the person's medicines. The pharmacist will use tools made for checking medicines in older people. The pharmacist will then send suggestions to the person's doctor. The doctor decides what to change. No medicine is changed without the doctor's agreement.
  • In the second group, people will keep taking the medicines their doctor already prescribed. These medicines are checked in the usual way, which is the same for all patients. The researchers will also look at these medicines with the tools made for older people, at the start and after six months, to compare the two groups. No suggestions from this review will be sent to the doctor.

The study does not test any new or experimental medicine. Every month, when the person comes to pick up their medicines, the pharmacist will check the medicine list. The pharmacist will write down any change and any problem the person reports.

The researchers will check the person's abilities three times: at the start, after three months, and after six months. They will also ask about quality of life, health and social conditions at the start and after six months.

Each person takes part for six months. What are the possible risks and benefits? In both groups, a person's medicines may change during the study. A medicine may be added, stopped or replaced after a review.

Medicines can cause new problems, such as side effects. This can happen with a new medicine. It can also happen with a medicine the person has taken for a long time. The pharmacist asks about such problems every month. Any change to a person's medicines is decided by their own doctor, as in normal care.

People in the study may or may not feel better. The researchers hope the results will help care for older people in Lebanon and in other countries.

What happens after the study? People in both groups keep receiving the usual care of their health center. Taking part does not change a person's right to care. Joining is a free choice. A person can stop at any time, and their care will not change.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

Scientific rationale:

Polypharmacy and potentially inappropriate prescribing (PIP) are associated with adverse drug events, drug-drug interactions, prescribing cascades, falls and functional decline in older adults. PIP covers both the use of medications whose risks outweigh their benefits and the omission of clinically indicated therapies. The WHO Integrated Care for Older People (ICOPE) framework reorients geriatric care toward the preservation of intrinsic capacity (IC), defined as the composite of physical and mental capacities an individual can draw upon, across cognition, locomotion, vitality, psychological status and sensory function. Explicit criteria such as STOPP/START allow structured identification of inappropriate medications and prescribing omissions, while implicit approaches grounded in individualized clinical judgment allow decisions to be tailored to patient context and values. The effect of combining both approaches on IC has not been evaluated in a randomized design. In Lebanon, where a rapid demographic transition coincides with economic crisis and sustained pressure on the healthcare system, ICOPE has not been implemented in primary care, IC has not been systematically studied, and pharmacotherapy optimization is not routinely integrated into geriatric care.

Setting and recruitment strategy:

The trial is conducted in the primary health care centers (PHCCs) operated by the Order of Malta Lebanon and distributed across the Lebanese territory. The study is sponsored by the National Institute of Public Health, Clinical Epidemiology and Toxicology-Lebanon (INSPECT-LB), with the Centre Hospitalier Universitaire de Toulouse as collaborating institution.

Recruitment runs in parallel at all sites over a four-month period, which distributes the enrollment burden across centers. Recruitment targets are allocated in proportion to regional population density and center capacity, with larger numbers drawn from the largest centers. Participants are identified on site during routine visits by trained PHCC staff, mainly pharmacists and triage nurses; no telephone-based or remote recruitment is conducted. Eligible individuals are long-standing beneficiaries of their center who attend regularly for medical services including monthly medication refills, which provides repeated and predictable contact points for screening without requiring an additional visit. In 2025, the participating centers served approximately 14,000 unique beneficiaries aged 65 years and over. Screening logs are reviewed per center on a bi-weekly basis by the principal investigator and the co-investigator to monitor recruitment progress.

Assessment schedule:

Data are collected prospectively at the PHCC through face-to-face interviews conducted by trained staff using a standardized questionnaire. The full assessment is administered at baseline (T0) and at six months (T6). At baseline, the following set of information is obtained to capture functional, sociodemographic and clinical characteristics.

Functional status is assessed using the Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) scales. These serve both as baseline measures and as eligibility confirmation, ensuring that participants are functionally independent; individuals who do not meet the threshold are not included.

Sociodemographic and center-related data include the geographic location of the center, source of referral and duration of attendance, together with age, sex, educational level, marital status, number of children where applicable, living arrangements, caregiver status, breadwinner status, place of residence (urban or rural), household crowding index, housing ownership, employment status and healthcare coverage.

Lifestyle characteristics and clinical parameters are assessed at T0 and T6 and encompass physical activity, sleep duration, sedentary behavior, caffeine intake, smoking, alcohol consumption, vital signs (heart rate, oxygen saturation, systolic and diastolic blood pressure), laboratory results and chronic diseases.

Frailty and sarcopenia are assessed at T0 and T6 using the Fried frailty phenotype and the SARC-F screening tool. Although these measures are typically part of the Step 2 mobility assessment within the ICOPE framework, they are administered to all participants at baseline following Step 1 basic assessment, to ensure comprehensive characterization of functional status.

Medication-related variables at baseline include the number of prescribed chronic medications, the total daily pill burden, a detailed medication list, and medication adherence assessed with the Lebanese Medication Adherence Scale adapted for the Primary Health Care setting (LMAS-PHC). Potentially inappropriate prescriptions (PIPs) are identified in all participants at baseline and at six months using the STOPP/START version 3 explicit criteria and an implicit approach. Throughout the six-month follow-up, the pharmacist updates the medication list at each monthly in-person refill visit, alongside routine counselling and education, and documents any medication change with its reason and any reported adverse event. Adherence is re-assessed with the LMAS-PHC at six months.

Quality of life is evaluated at T0 and T6 with the WHO Quality of Life-OLD brief instrument. Social determinants of health are assessed at the same timepoints using the Socioeconomic Status for Primary Healthcare (SES-PHC) scale, the Steps to Better Health Questionnaire (STBH-Q), the Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being scale (FACIT-Sp-12, version 4), the UCLA Loneliness Scale (ULS-8, version 3) and the European Health Literacy Survey Questionnaire (HLS-EU-Q16).

For data elements that are clinically documented rather than self-reported, such as vital signs, laboratory results, chronic diseases and current medication lists, information may be retrieved from PHENICS, the health information system deployed by the Lebanese Ministry of Public Health across all PHCCs. This minimizes interview burden while ensuring the accuracy and completeness of routinely recorded clinical data.

Implementation of the ICOPE framework:

The ICOPE framework is implemented following a real-life approach. Step 1 basic assessment (screening) is systematically performed for all participants across the intrinsic capacity domains defined by WHO: cognition, locomotion, vitality, vision, hearing and psychological status, with vision and hearing forming the sensory domain at the scoring stage. Basic assessment enables early detection of functional decline and supports the assessment of overall intrinsic capacity. It is administered at baseline, at three months (T3) and at six months. The T3 assessment is limited to Step 1; it provides three IC measurements per participant, supports the estimation of individual trajectories, and limits the impact of loss to follow-up before T6.

Step 2 in-depth assessments, using validated tools, are conducted at baseline and at six months, in line with WHO recommendations for biannual evaluation. They are performed selectively, for the domains concerned, and are initiated only after Step 1 alerts have been reviewed and appropriately managed, in order to confirm suspected impairment or screening-detected decline in the corresponding domain. Participants screened abnormal in one or two domains undergo a Step 2 assessment targeted to those domains, while a comprehensive Step 2 evaluation across all domains is undertaken when impairment is identified in at least three domains.

Sample size justification:

The sample size was estimated for the primary outcome, IC. In the absence of published data in a comparable population, assumptions were derived from preliminary unpublished data from the ongoing INSPIRE study at CHU de Toulouse, France, in which participants aged 65 years and over had a mean IC score of 79.27 (SD 9.47; n = 549), with greater dispersion among those taking five or more medications. A between-group difference of 2.5 IC points (79.0 versus 81.5) was considered clinically plausible, and a conservative standard deviation of 9 points was retained to avoid underestimating variability in an older polymedicated population. With a two-sided alpha of 0.05, 80% power and 1:1 allocation, 203 participants per group were required. To account for an anticipated 10% rate of loss to follow-up, withdrawal of consent and missing primary-outcome data, this figure was inflated by dividing by (1 - 0.10), giving 226 participants per group.

A second, independent estimation was performed to verify the adequacy of this figure under the planned adjusted analysis. Using G*Power (version 3.1.9.7), a multiple linear regression model (fixed model, R² increase) was applied to detect the effect of the pharmacotherapy optimization intervention on IC improvement with adjustment for baseline characteristics. Parameters were set as follows: a small anticipated effect size (f² = 0.02), a two-tailed alpha of 0.05, a power of 0.80, one tested predictor (the intervention) and 30 total predictors accounting for potential confounders, including age, sex, number of medications, comorbidities and baseline intrinsic capacity measures. Under these assumptions, a minimum of 395 participants was required, corresponding to 439 participants after the same 10% inflation.

The two approaches therefore converged on a comparable magnitude, and the larger, more conservative estimate of 452 participants (226 per group) was retained as the recruitment target; at this sample size, the adjusted regression model attains a statistical power of 0.85, providing an additional margin for the multivariable analysis.

Statistical analysis:

Analyses will be performed using SPSS and R, with a two-sided alpha of 0.05 and 95% confidence intervals. Baseline characteristics will be described overall and by arm, without significance testing of between-arm differences. Analyses follow the intention-to-treat principle: all randomized participants from both arms will be analyzed in the group to which they were allocated.

The IC score is the additive ICOPE Step 1 composite score. Each domain is rescaled to 0-100 using the percentage of maximum possible method, and the score is the arithmetic mean of five domains: cognition, locomotion, vitality, sensory capacity (vision and hearing averaged) and psychological status. Step 2 data are not used in the derivation of this score.

The intervention effect on IC will be estimated using a linear mixed-effects model including group, time (T0, T3 and T6) and the group-by-time interaction as fixed effects, participant-specific random intercepts and, if supported by model fit, random slopes for time, adjusted for relevant baseline covariates. The distribution of IC scores by arm will be described in relation to published French age- and sex-specific reference centiles and to preliminary Lebanese centiles. Continuous secondary outcomes will be analyzed using the same mixed-effects approach.

Baseline PIPs, identified with the STOPP/START version 3 criteria and an implicit approach, will be described by number and type for the full baseline sample and by arm, with correlates examined using multivariable logistic regression for the presence of at least one PIP and multivariable linear regression for the number of PIPs per participant. The effect of the intervention on the number of PIPs per participant between baseline and six months will be estimated using the same mixed-effects approach.

No imputation will be performed. Baseline covariates are collected in full, and the likelihood-based mixed-effects models use all available observations under a missing-at-random assumption. Step 2 data not indicated by Step 1 basic assessment are structurally absent by design and are not treated as missing.

Exploratory analyses, conducted where data permit and considered hypothesis-generating, include a bifactor confirmatory factor analysis to derive a latent IC score, retained only if model fit and factor-score reliability are acceptable; preliminary Lebanese age- and sex-specific IC centile curves generated with GAMLSS; IC centile transitions between baseline and six months by arm; time from randomization to first medication change analyzed with Cox proportional hazards regression; psychometric evaluation of the study scales; and domain-level analyses of Step 2 data restricted to participants with impairment identified at basic assessment.

Safety monitoring and trial conduct:

A data monitoring committee of four members, independent of the sponsor, the collaborating institution, the host institution and the funders, reviews the monthly medication review records throughout the trial and meets monthly from the initiation of data collection. No interim analysis is planned, given the six-month follow-up and the profile of the intervention, which involves no novel molecule, no experimental treatment, no placebo and no withholding of indicated care, and in which all prescribing decisions remain the responsibility of the treating physician. Site pharmacists report adverse events to the principal investigator within 24 hours of identification; serious adverse events are reported to the ethics committee in accordance with its requirements. Site visits to the participating centers are conducted every one to two months to verify data quality and protocol compliance; the interval may be extended where road safety or security conditions temporarily prevent travel.

연구 유형

중재적

등록 (추정된)

452

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

  • 이름: Jihan Safwan, PharmD, MPH, PhD candidate
  • 전화번호: 009613643918
  • 이메일: jihansafwan@gmail.com

연구 장소

      • Beirut, 레바논
        • Order of Malta Lebanon
        • 연락하다:
        • 연락하다:
        • 부수사관:
          • Jihan Safwan, PharmD, MPH, PhD candidate

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

65년 이상 (고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Lebanese patients
  2. Older patients ≥ 65 years of age
  3. Diagnosed and treated for at least two chronic diseases*
  4. Resorting to an OML PHCC and benefiting from chronic medication dispensing services for at least one year
  5. Treated with at least five chronic medications
  6. Autonomous (non-dependent) patients living in their houses
  7. Signed the consent form *Chronic disease is defined as any condition that lasts twelve months or more and requires the administration of a chronic medication.

Exclusion Criteria:

  1. Non-Lebanese patients
  2. Patients < 65 years of age
  3. Patients diagnosed with only one chronic disease
  4. Beneficiaries newly registered in the PHCC
  5. Patients only presenting to the PHCC for acute consultations and non-chronic medications dispensing services
  6. Patients with advanced-stage cognitive impairment
  7. Patients diagnosed with cancer
  8. Dependent patients or patients residing in specialized care homes/hospitals
  9. Persons presenting to the PHCC on behalf of the older patients to collect the monthly medication refill

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Structured pharmacotherapy optimization

Intervention-group participants at each Order of Malta Lebanon primary health care center (PHCC) will undergo structured pharmacotherapy optimization using the STOPP/START explicit criteria and the implicit prescribing approach, supervised by the research team with support from an expert panel in clinical pharmacy and geriatric pharmacotherapy. Patient cases will be reviewed in weekly meetings between researchers, PHCC pharmacists, and treating physicians, where identified prescribing issues and proposed optimization strategies will be discussed. Final prescribing decisions will remain with the treating physician and his/her clinical judgement, who, after discussing the agreed changes with the patient at the next monthly medication-refill visit, will amend the prescription as clinically appropriate and update it in the health information system. The pharmacist will then provide the participant with the updated medication list and individualized education on the optimized regimen.

A structured medication-review and optimization intervention based on STOPP/START explicit criteria, an implicit medication-review approach, and clinical judgment. Medication-related problems and potential optimization strategies are reviewed with the research team and treating physicians. Final prescribing decisions remain the responsibility of the treating physician. Pharmacists subsequently provide participants with medication-related education and updated medication lists during monthly refill visits.

활성 비교기: Usual care

Control-group participants will receive usual care at the participating Order of Malta Lebanon primary health care centers, without the structured pharmacotherapy optimization based on the STOPP/START criteria and the implicit prescribing approach. Usual care comprises multidisciplinary medication reconciliation, routine medication management, patient education and counseling, and dispensing.

Participants receive the usual multidisciplinary medication reconciliation provided at the participating primary health care centers (applied to all patients of all ages and not specifically based on the explicit criteria and implicit approach for older patients).

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in intrinsic capacity composite score
기간: Baseline, 3 months, and 6 months post-randomization

Intrinsic capacity is measured as the composite score derived from the five WHO ICOPE domains in Step 1 basic assessment, analyzed as change from baseline (T0) to six months post-randomization (T6), and summarized as the adjusted between-group mean difference. Intrinsic capacity is also assessed at three months (T3), and all three time points are included in the longitudinal analysis. Participants will also be positioned on French age- and sex-specific intrinsic capacity reference centiles and on preliminary Lebanese centiles. Transitions across centile categories between baseline and six months are compared between arms.

Baseline, 3 months, and 6 months post-randomization

2차 결과 측정

결과 측정
측정값 설명
기간
Change in the number of potentially inappropriate prescriptions per participant
기간: Baseline and 6 months post-randomization

Potentially inappropriate prescriptions (PIPs) are identified in all participants using the STOPP/START version 3 explicit criteria combined with an implicit prescribing approach. The outcome is the change in the number of PIPs per participant from baseline to six months, summarized as the adjusted between-group mean difference, together with the distribution of PIPs by type in each arm. As prescriptions in the control group may also be modified during follow-up as part of usual care, PIPs are reassessed at six months in both groups. Baseline PIPs are additionally described for the full sample and by arm.

Baseline and 6 months post-randomization
Change in quality of life (WHOQOL-OLD, brief format)
기간: Baseline and 6 months post-randomization

The change in QOL is analyzed as change from baseline to six months, summarized as the adjusted between-group mean difference. The WHOQOL score ranges between 24 and 120.

Baseline and 6 months post-randomization
Change in socioeconomic status (SES-PHC scale)
기간: Baseline and 6 months post-randomization

The change in SES-PHC scale is analyzed as change from baseline to six months, summarized as the adjusted between-group mean difference. The score ranges between 7 and 29.

Baseline and 6 months post-randomization
Change in score on the Steps to Better Health Questionnaire (STBH-Q)
기간: Baseline and 6 months post-randomization

The change in score on the Steps to Better Health Questionnaire (STBH-Q) is analyzed as change from baseline to six months, summarized as the adjusted between-group mean difference. Score of the STBH-Q ranges between 0 and 152.

Baseline and 6 months post-randomization
Change in spiritual well-being (FACIT-Sp-12, version 4)
기간: Baseline and 6 months post-randomization

The Change in spiritual well-being (FACIT-Sp-12, version 4) is analyzed as change from baseline to six months, summarized as the adjusted between-group mean difference. The FACIT score ranges between 0 and 48.

Baseline and 6 months post-randomization
Change in loneliness (UCLA Loneliness Scale, ULS-8, version 3)
기간: Baseline and 6 months post-randomization

The Change in loneliness (UCLA Loneliness Scale, ULS-8, version 3) is analyzed as change from baseline to six months, summarized as the adjusted between-group mean difference. The UCLA score ranges between 8 and 32.

Baseline and 6 months post-randomization
Change in health literacy (HLS-EU-Q16)
기간: Baseline and 6 months post-randomization

The Change in health literacy (HLS-EU-Q16) is analyzed as change from baseline to six months, summarized as the adjusted between-group mean difference. The HLS score ranges between 0 and 16.

Baseline and 6 months post-randomization
Change in frailty status (Fried frailty phenotype)
기간: Baseline and 6 months post-randomization

The Change in frailty status (Fried frailty phenotype) is analyzed as change from baseline to six months, summarized as the adjusted between-group mean difference. The Fried frailty score ranges between 0 and 5 criteria.

Baseline and 6 months post-randomization
Change in sarcopenia screening score (SARC-F)
기간: Baseline and 6 months post-randomization

The Change in sarcopenia screening score (SARC-F) is analyzed as change from baseline to six months, summarized as the adjusted between-group mean difference. The SARC-F score ranges between 0 and 10.

Baseline and 6 months post-randomization
Change in medication adherence (LMAS-PHC)
기간: Baseline and 6 months post-randomization

The Change in medication adherence (LMAS-PHC) is analyzed as change from baseline to six months, summarized as the adjusted between-group mean difference. LMAS score ranges between 0 and 66.

Baseline and 6 months post-randomization
Proportion of participants with at least one reported adverse event
기간: Randomization through six months

Adverse events reported by participants and documented by the pharmacist at each monthly in-person medication refill visit, analyzed as event occurrence over the follow-up period and summarized as proportions by arm.

Randomization through six months
Proportion of participants with at least one change in medication prescription
기간: Randomization through six months

Any medication discontinuation, dose adjustment, therapeutic substitution or initiation documented by the pharmacist at each monthly in-person refill visit, with its reason; summarized as proportions by arm.

Randomization through six months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 연구 책임자: Pascale Salameh, PharmD, MPH, PhD, HDR, National Institute of Public Health, Clinical Epidemiology, and Toxicology-Lebanon (INSPECT-LB)
  • 연구 책임자: Philippe Cestac, PharmD, PhD, HDR, Centre Hospitalier Universitaire (CHU) de Toulouse
  • 연구 책임자: Mathilde Strumia, PharmD, PhD, Centre Hospitalier Universitaire (CHU) de Toulouse
  • 수석 연구원: Lina Traboulsi, PharmD, MPH, PhD, HDR, National Institute of Public Health, Clinical Epidemiology, and Toxicology-Lebanon (INSPECT-LB) and Order of Malta Lebanon

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 23일

기본 완료 (추정된)

2027년 8월 1일

연구 완료 (추정된)

2027년 8월 1일

연구 등록 날짜

최초 제출

2026년 10월 4일

QC 기준을 충족하는 최초 제출

2026년 10월 4일

처음 게시됨 (실제)

2026년 10월 8일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 4일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 2026ERC-013-LIUSOP

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .